SCHEDULE: Deep Track Capital Exits 89bio, Inc. Stake

Deep Track Capital and its affiliates have reported a complete divestment of their beneficial ownership in 89bio, Inc., holding 0% of common stock as of December 31, 2025.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin reported 0% beneficial ownership of 89bio, Inc. common stock.
• This filing is Amendment No. 3 to a Schedule 13G, indicating a previous ownership stake that has now been fully divested.
• The beneficial ownership percentage is calculated based on 148,308,250 common shares outstanding as of July 31, 2025, as reported in 89bio's 10-Q filing.
• The reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, as the complete divestment by a specialized biotech investor like Deep Track Capital typically signals a lack of confidence in the company's future performance or strategic direction.

Negatives

• Deep Track Capital, a specialized biotechnology investor, has fully divested its stake in 89bio, Inc., signaling a potential lack of confidence or a strategic shift away from the company.
• The complete exit of a significant institutional investor can put downward pressure on the stock price and deter other potential investors.

Risks

• The divestment by a specialized biotech fund could be interpreted by the market as a negative signal regarding 89bio's future prospects or pipeline.
• Reduced institutional ownership might lead to increased stock volatility and decreased liquidity.

Future Outlook

The filing does not contain forward-looking statements or guidance from 89bio, Inc. It solely reports the current beneficial ownership status of Deep Track Capital.

Industry Context

StockSavvy.ai notes that the complete divestment by Deep Track Capital, a fund focused on biotechnology investments, could be a notable event within the biotech sector. Such exits by specialized funds often prompt other investors to re-evaluate their positions in the company, especially if the fund is known for its deep industry expertise and rigorous due diligence. This move might suggest a reassessment of 89bio's drug pipeline, market potential, or competitive landscape by a sophisticated industry player.

Stakeholder Impact

• Shareholders: Existing shareholders may face downward pressure on the stock price due to the divestment and potential loss of institutional support.
• Potential Investors: The exit of a specialized fund could deter new institutional investors from considering a position in 89bio, Inc.

Key Dates

Recommendation

The complete divestment by a specialized biotechnology investment firm like Deep Track Capital, as indicated by this Amendment No. 3 filing reporting 0% ownership, is a strong negative signal. It suggests that a sophisticated investor with deep industry knowledge has lost confidence in 89bio, Inc.'s prospects. This could lead to significant downward pressure on the stock price and warrants a 'sell' recommendation for investors to mitigate potential losses or reallocate capital to more promising opportunities.

Keywords

89bio Inc., Deep Track Capital, Deep Track Biotechnology Master Fund, David Kroin, Schedule 13G, Beneficial Ownership, Divestment, Biotechnology, Institutional Investor, Common Stock